Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: genetics + therapy + web  Related to the article below (Last Update: 8/5/2008)


MLive.com
Contact the Newspaper:
MLive.com, MI - Aug 3, 2008
Stuart Bauer | The Flint JournalDean laughs as bubbles are blown at him during therapy. The CDC contends, on its Web site, that "there is no convincing ...
VIRxSYS to Host a Web Conference to Announce Clinical Trial Update
MarketWatch - Jul 21, 2008
Unlike anti-retroviral drugs, VRX496 appears to bind to the RNA of HIV, changing the genetics and biology of the virus, including the molecular diversity of ...
Finding the Golden Genes
Science News - Jul 18, 2008
Scientists are fighting genetics with genetics, so to speak, enlisting the latest technologies for gene sequencing or for profiling the activity of proteins ...
What's New in Orthopaedic Research
Journal of Bone and Joint Surgery (subscription) - Aug 1, 2008
The use of gene therapy continues to be developed for the treatment of arthritis, although not with genetic causes of the disease as a target. ...
Home genetic tests: How much do you really want to know?
Independent, UK - Jul 11, 2008
Those who discover they are at greater risk might think carefully about taking oestrogen or hormone-replacement therapy and having regular screening. ...
Prana Selected for "Hot Topics" and Alzheimer's Association Press ...
CNNMoney.com - Jul 17, 2008
July 27 at 10:50am Professor, Department of Neurology, Harvard Medical School, USA Genetic association studies in Alzheimer's disease -- Genetics can be ...PRAN
Fetal alcohol spectrum dims bright futures
Tucson Citizen, AZ - Jul 28, 2008
Dr. Robert Erickson, the Holsclaw professor of human genetics and inherited diseases at the University of Arizona, called Kellerman's work "invaluable. ...
The Happiness Hype
OhmyNews International, South Korea - Jul 21, 2008
Haidt believes it does, but is too simplistic given that our set point for happiness is largely determined by genetics. Although we have some room to ...
LabCorp Announces Availability of ColoSure
Carolina Newswire (press release), NC - Jul 14, 2008
?ColoSure is a significant addition to LabCorp?s family of advanced molecular tests, to aid in the detection, diagnosis, prognosis, therapy selection, ...LH
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday ...
Trading Markets (press release), CA - Jul 25, 2008
"Ceplene, in conjunction with IL-2, is the first therapy shown to significantly prolong leukemia-free survival and prevent relapse in AML patients in first ...OTC:WNEA - PINK:MGRN - EPCT
Source: Google News

… Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy -
MK Higashi, DL Veenstra, LM Kondo, AK Wittkowsky, … - JAMA, 2002 - Am Med Assoc
... Ideally, this study would be large enough to make meaningful comparisons of the
risk-benefit ratio of warfarin therapy in genetic subgroups (eg, *2/*2, *3/*3). ...

Combination Genetic Therapy to Inhibit HIV-1 -
DS Strayer, F Branco, J Landr?, M BouHamdan, F … - Molecular Therapy, 2002 - nature.com
Original Article. Molecular Therapy (2002) 5, 33?41; doi: 10.1006/mthe.2001.0513.
Combination Genetic Therapy to Inhibit HIV-1. David ...

Gene Therapy Insertional Mutagenesis Insights -
UP Dave, NA Jenkins, NG Copeland - Science, 2004 - sciencemag.org
... that does not support current Web standards. ... Gene Therapy Insertional Mutagenesis
Insights. ... Mouse Cancer Genetics Program, National Cancer Institute, Center for ...

Aerosol Delivery of Robust Polyethyleneimine?DNA Complexes for Gene Therapy and Genetic Immunization -
CL Densmore, FM Orson, B Xu, BM Kinsey, JC Waldrep … - Molecular Therapy, 2000 - nature.com
... mthe.1999.0021. Aerosol Delivery of Robust Polyethyleneimine? DNA Complexes
for Gene Therapy and Genetic Immunization. Charles L ...

Gene therapy restores vision in a canine model of childhood blindness -
GM Acland, GD Aguirre, J Ray, Q Zhang, TS Aleman, … - Nature Genetics, 2001 - nature.com
... information is available on the Nature Genetics web site (http ... Bennett, J. & Maguire,
A. Gene therapy for ocular ... Redmond, T. & Hamel, C. Genetic analysis of ...

Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless … -
PS Reddy, K Sakhuja, S Ganesh, L Yang, D Kayda, T … - Molecular Therapy, 2002 - nature.com
... and Sheila Connelly 1. 1 Genetic Therapy, Inc. (A Novartis Company), 9
West Watkins Mill Road, Gaithersburg, Maryland 20878, USA; ...

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy -
JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S … - Science, 2004 - sciencemag.org
... for citing articles in: ISI Web of Science ... extend the emerging paradigm whereby genetic
alterations in ... although randomized trials of cytotoxic therapy with or ...

… Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in … -
L Wang, TC Nichols, MS Read, DA Bellinger, IM … - Molecular Therapy, 2000 - nature.com
... corrected the bleeding disorder of hemophilia B dogs, supporting the feasibility
of using AAV-based vectors for liver-targeted gene therapy of genetic diseases ...

In Vivo Hepatic Adenoviral Gene Delivery Occurs Independently of the Coxsackievirus?Adenovirus … -
T Smith, N Idamakanti, H Kylefjord, M Rollence, L … - Molecular Therapy, 2002 - nature.com
... 1 Genetic Therapy, A Novartis Company, 9 West Watkins Mill Rd. Gaithersburg, Maryland,
20878, USA. Correspondence: Susan C. Stevenson, Fax: (301) 258-4680. ...

GENE THERAPY: Second Child in French Trial Is Found to Have Leukemia -
E Marshall - Science, 2003 - sciencemag.org
... are using a browser that does not support current Web standards. ... cancer might have
been triggered by a harmful genetic mutation not related to the therapy. ...

Source: Google Scholar

Genetics Research On Host Responses To HIV May Lead To Improved Therapies And A Vaccine
The first genome-wide association study of an infectious disease, conducted by an international group of researchers through the Center for HIV/AIDS Vaccine Immunology (CHAVI), has yielded a new understanding of why some people can suppress virus levels following HIV infection. "The clearer picture of host responses to the virus achieved through this examination of genomes could lead to improved HIV therapies and provides new targets for vaccine developers," says Elias A. Zerhouni, M.D., director of the National Institutes of Health (NIH). CHAVI, which is led by Barton Haynes, M.D., of Duke University, Durham, N.C., was established in 2005 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
CHAVI's host genetics team, led by David Goldstein, Ph.D., also of Duke University, included scientists from several European countries and Australia who formed a consortium, EuroCHAVI, to perform this study. The investigators identified three gene variants, two of which are linked to an infected person's ability to control HIV viral load and a third that is implicated in disease progression to AIDS. The research is being published by Science on the Science Express Web site.

"CHAVI is designed to foster collaborative research to overcome roadblocks that have impeded HIV vaccine development," says NIAID Director Anthony S. Fauci, M.D. "The insights into genetic factors influencing host control of HIV revealed by this work exemplify the power of such collective investigations."

Genome-wide association studies aim to identify genetic variations among people that can be tied to variations in disease susceptibility. Recent genome-wide association studies have found genetic markers linked to increased risk of such ailments as diabetes, cancer and heart disease. The CHAVI investigators are the first to apply genome-wide association techniques to an infectious disease.

"People vary greatly in their vulnerability to HIV infection," notes Dr. Haynes. "In particular, there are striking and largely unexplained differences between individuals in the degree to which they are able to hold viral levels to a low set point in the period soon after infection." If scientists could pinpoint the gene variants that help some people control HIV infection--or avoid it altogether--they might be able to rationally design therapies or vaccines to mimic these naturally occurring genetic advantages, he notes.

In 2006, CHAVI researchers launched an effort to pool genetic data from HIV-positive individuals who had enrolled in nine studies based throughout Europe and in Australia. Together, these studies contained information on more than 30,000 individuals. From this pooled cohort, the CHAVI scientists ultimately chose 486 DNA samples--representing the genomes of 486 HIV-positive people whose viral load set points had been carefully and accurately measured at multiple time points--for the genome-wide association study.
The scientists applied the genome samples to gene chips dotted with more than 550,000 human gene variants, called single nucleotide polymorphisms or SNPs. The sweep of genomes found three SNPs that were strongly associated with either viral load set point or disease progression. The two variants associated with viral load can explain 15 percent of the total variation among all infected individuals, the scientists estimate.

One of the identified variants is near a human immune gene called HLA-C, and may provide a new route for HIV vaccine developers to explore, says Dr. Goldstein. People with the identified variant are thought to make more of the gene's product than people who lack this presumably protective genetic variant. A consequence of this extra production of HLA-C protein, researchers hypothesize, is that the immune system is better able successfully identify and remove HIV-infected cells, thus keeping viral load set points low for long periods.

HIV has many ways to defend itself from immune system efforts to eliminate it. One defense is the ability of an HIV gene, nef, to decrease the production of two related immune system proteins, HLA-A and HLA-B. Nef, scientists believe, is not able to similarly hamper the expression of HLA-C. If scientists could design a vaccine to enhance HLA-C-mediated immune responses, they might be able to hit HIV at a vulnerable point, says Dr. Goldstein. Although HLA-C had previously been suspected of contributing to HIV control, this genome-wide study is the first to confirm the association, he adds.

The CHAVI investigators are currently building on these studies of polymorphisms to pinpoint the specific human gene variants that influence HIV replication.

"We applaud the CHAVI investigators for the highly collaborative nature of this work. It demonstrates that answers to important questions, requiring analysis of large amounts of clinical specimens, can be obtained quickly," says Peggy Johnston, Ph.D., director of NIAID's Vaccine Research Program.

CHAVI is a consortium of researchers from five institutions. In addition to Duke University, the institutions are the University of North Carolina-Chapel Hill; the University of Alabama-Birmingham; Harvard Medical School, Boston, Mass.; and Oxford University, U.K. NIAID established CHAVI in response to recommendations made by the Global HIV Vaccine Enterprise, and its goals are linked to those of the Enterprise. Endorsed by world leaders at a G-8 summit in June 2004, the Enterprise is a virtual consortium of independent organizations committed to accelerating development of effective vaccines against HIV/AIDS through the creation and implementation of a shared strategic scientific plan, mobilization of resources, and greater coordination among HIV vaccine researchers worldwide. Additional information about the Global Enterprise can be found at http://www.hivvaccineenterprise.org/. For additional information about CHAVI, visit http://www.chavi.org/.

NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.eurekalert.org/pub_releases/2007-07/nioa-fgs071907.php.

Reference: J Fellay et al. Identification of major determinants of the host control of HIV-1 through a whole-genome association study. Science Express DOI: 10.1126/science.1143767 (published online July 19, 2007.)

News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov/.

Source: Anne A. Oplinger
NIH/National Institute of Allergy and Infectious Diseases
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.